The aim of the study was to explore the extent of thrombocytopenia (TCP), anaemia and leucopenia in patients with hepatitis C and evaluate how they impact the management of antiviral therapy, the attainment of sustained virological response (SVR), and some therapy-related adverse events. The Scottish Hepatitis C Clinical Database was used in this retrospective study. The prevalence of TCP, anaemia and leucopenia was evaluated. The impact of the three deficiencies on antiviral therapy management, serious adverse events and SVR attainment was assessed in patients who received therapy.
|Number of pages||7|
|Journal||European Journal of Gastroenterology and Hepatology|
|Early online date||21 Dec 2015|
|Publication status||Published - Apr 2016|
- Hepatitis C
- antiviral therapy
Wang, H., Innes, H., Hutchinson, S., Goldberg, D., Allen, S., Barclay, S. T., Bramley, P., Fox, R., Fraser, A., Hayes, P., Kennedy, N., Mills, P. R., & Dillon, J. F. (2016). The prevalence and impact of thrombocytopenia, anaemia and leucopenia on sustained virological response in patients receiving hepatitis C therapy: evidence from a large ‘real world’ cohort. European Journal of Gastroenterology and Hepatology, 28 (4), 398-404. https://doi.org/10.1097/MEG.0000000000000556